CIHI: On December 17, the Canadian Institute for Health Information (CIHI) published statistics1 on drug spending, finding that in 2018, around 40% of drug spending was spent on 2% of beneficiaries. Out of this 2%, three out of five individuals used a drug therapy that cost $10,000 or more per year (e.g. antivirals or biologics for rheumatoid arthritis/Crohn’s disease). The top increases in drug spending over the past 5 years were for drug classes with average annual costs of $10,000 or more.
PMPRB Meds Entry Watch: In January 2020, the PMPRB released the Meds Entry Watch 2018, which analyzes information about medicines approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada in 2017 and 2018.
Consistent with the CIHI report, one of the key findings is the continued upward trend in the entry of high-cost products (such as orphan drugs and oncology products), with nearly two thirds of the medicines approved internationally in 2017 having treatment costs over $10,000 per year, or $5,000 per 28-day cycle for oncology medicines.
References
1. Link to the original source is no longer available. See the 2019 report for more details.
Related Publications & Articles
-
CDA–AMC (formerly CADTH) announces several pilot projects, including Target Zero initiative
CADTH is now known as Canada’s Drug Agency (CDA-AMC or CDA). Its mandate extends beyond CADTH’s mandate.Read More -
PMPRB releases Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines
On June 26, 2024, the Patented Medicine Prices Review Board (PMPRB) released a Discussion Guide for its Phase 2 Consultations on its New Guidelines.Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More